Riquent "Approvable" For Lupus; FDA Says Ongoing Study Could Be Enough
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla Pharmaceuticals hopes running a parallel study alongside the ongoing confirmatory trial for its lupus agent Riquent will satisfy the requirements set out in FDA’s Oct. 14 "approvable" letter.